Real-Time EquityWire is available only to registered users. This is best for professional traders and people who track markets actively.Real-Time EquityWire is available only to registered users. This is best for professional traders and people who track markets actively.
The Delhi High Court has lifted the bar on the sale and marketing of Sigrima by Zydus Lifesciences Ltd., which was allegedly biologically similar to F-Hoffmann-LaRoche AG's "Perjeta/Pertuzumab". The high court has rejected F-Hoffmann-LaRoche AG's plea seeking an interim injunction against Zydus Lifesciences for Sigrima.
Share this Story:
